Search results for " arthritis"

showing 10 items of 629 documents

Combined treatment of hidradenitis suppurativa with intense pulsed light (IPL) and radiofrequency (RF)

2019

BACKGROUND Hidradenitis suppurativa is a chronic inflammatory disease with high burden. Treatment options are often unsatisfactory. We assessed the effect of a combination therapy of intense pulsed light (IPL) and radiofrequency (RF). METHODS The explorative study included 47 patients and was performed as a prospective, monocentric, randomized, three-arm parallel-group design trial with a prior 12 weeks observation period. Treatment arms were IPL and RF monotherapies or IPL + RF combination therapy. After 12 weeks, all patients received IPL + RF for additional 12 weeks (cross-over). Primary endpoint was the change in active lesion numbers, secondary endpoint the change in Dermatology Qualit…

AdultMalemedicine.medical_specialtyCombination therapymedicine.medical_treatmentDermatologyIntense pulsed lightChronic inflammatory diseaseLesionYoung Adult030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineCombined treatmentmedicineClinical endpointHumansHidradenitis suppurativaProspective Studies030203 arthritis & rheumatologybusiness.industryIntense Pulsed Light TherapyTreatment optionsMiddle AgedRadiofrequency Therapymedicine.diseaseCombined Modality TherapyDermatologyHidradenitis SuppurativaTreatment OutcomeQuality of LifeFemalesense organsmedicine.symptombusinessJournal of Dermatological Treatment
researchProduct

A discrete-choice experiment to assess patients’ preferences for osteoarthritis treatment: An ESCEO working group

2020

Objective: To evaluate the preferences of patients with osteoarthritis for treatment.Methods: A discrete-choice experiment was conducted among adult OA patients who were presented with 12 choice sets of two treatment options and asked in each to select the treatment they would prefer. Based on literature reviews, expert consultation, patient survey and expert meeting, treatment options were characterized by seven attributes: improvement in pain, improvement in walking, ability to manage domestic activities, ability to manage social activities, improvement in overall energy and well-being, risk of moderate/severe side effects and impact on disease progression. Random parameters logit model w…

AdultMalemedicine.medical_specialtyDiscrete choice experimentOsteoarthritisOutcomes03 medical and health sciences0302 clinical medicinePHYSICIANSRheumatologySurveys and QuestionnairesOsteoarthritisMedicineHumans030212 general & internal medicineAgedOutcome030203 arthritis & rheumatologyddc:616HIPbusiness.industryDisease progressionDiscrete-choice experimentTreatment optionsPatient PreferencePatient preferencesmedicine.diseaseLatent class modelPreferenceEuropeInstitutional repositoryAnesthesiology and Pain MedicineLogistic ModelsPhysical therapyPatient surveyFemaleKNEEOsteoarthritiHEALTHbusiness
researchProduct

Surgery during etanercept therapy in patients with rheumatoid arthritis: is it time to follow patient preferences?

2008

Tumor necrosis factor (TNF)-a inhibitors, such as etanercept and infliximab, improve symptoms and function in patients affected by rheumatoid arthritis (RA) [1, 2] and, therefore, are playing an increasing role in the management of this disease. However, interference with endogenous TNF-a signalling has been reported to alter both normal inflammatory responses in tissue healing and infection surveillance [2, 3]. To our knowledge, the rates of surgery in RA are decreasing. However, with the duration of antiTNF therapy, the number of patients under these agents having surgery will be increasing. These data raise the question of whether TNF-inhibitors can be safely used in RA patients who shou…

AdultMalemedicine.medical_specialtyDiseaseReceptors Tumor Necrosis FactorEtanerceptEtanerceptArthritis RheumatoidPostoperative ComplicationsInternal MedicinemedicineOutpatient clinicHumansElective surgeryWound Healingbusiness.industryContraindicationsAnti-Inflammatory Agents Non-SteroidalMiddle Agedmedicine.diseaseInfliximabSurgeryItalyPatient SatisfactionRheumatoid arthritisImmunoglobulin GSurgical Procedures OperativeCohortEmergency MedicineQuality of LifeMethotrexateFemalebusinessmedicine.drugInternal and emergency medicine
researchProduct

[Hearing impairment in patients with rheumatoid arthritis].

2007

To evaluate the characteristics of hearing loss (HL) in patients with rheumatoid arthritis (RA).A comparative case-control study was performed with 194 patients and 107 healthy subjects. All of them were submitted to pure-tone audiometry and detection of inflammatory parameters and Western blot for anticochlear antibodies.HL was detected in 42.7 % of patients with RA (15.9 % in controls; P.001). This was sensorineural in 38.6 %. Three or more altered blood parameters appeared in 28.9 % of patients with RA (17.6 % in controls; P.01). We observed positive Western blot in 12 % of patients with RA and HL and none among healthy controls.There is a predisposition to HL, mainly sensorineural, in R…

AdultMalemedicine.medical_specialtyHearing lossArthritisArthritis RheumatoidInternal medicinemedicineHumansIn patientHearing Lossmedicine.diagnostic_testbiologybusiness.industryCase-control studyGeneral MedicineMiddle Agedmedicine.diseaseSurgeryRheumatoid arthritisCase-Control Studiesbiology.proteinFemalePure tone audiometryAudiometryAntibodymedicine.symptombusinessActa otorrinolaringologica espanola
researchProduct

Deaths Associated with Ankylosing Spondylitis in France from 1969 to 2009.

2017

Objective.To describe deaths for which ankylosing spondylitis (AS) was on death certificates in France.Methods.Death certificates in which AS was indicated were evaluated. Standard mortality ratio (SMR) was assessed.Results.AS appeared in 2940 death certificates. The mortality rate of AS seemed stable. The most frequent initial causes were diseases of the circulatory system [28.3% in the International Classification of Diseases, 10th ed (ICD-10)]. SMR adjusted for age and sex were 2.1 (95% CI 1.45–2.91) for infections and 0.43 (0.36–0.5) for cancers (ICD-10 period).Conclusion.This study found an increase in mortality from infectious and external causes of death; conversely, patients with AS…

AdultMalemedicine.medical_specialtyImmunologyAge and sexDeath Certificates03 medical and health sciences0302 clinical medicineRheumatologyInternal medicineCause of DeathmedicineImmunology and AllergyHumansSpondylitis Ankylosing030212 general & internal medicineAged030203 arthritis & rheumatologyAged 80 and overAnkylosing spondylitisbusiness.industryMortality rateCancerMiddle Agedmedicine.diseaseSurgeryStandardized mortality ratioFemaleDeath certificateFrancebusinessThe Journal of rheumatology
researchProduct

Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis With Polyangiitis: Data From a European Collaborative Study.

2021

OBJECTIVE To describe the efficacy and safety of biologics for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA). METHODS A retrospective European collaborative study was conducted in patients with EGPA who received treatment with biologics for refractory and/or relapsing disease. RESULTS Among the 147 patients with EGPA included in the study, 63 received rituximab (RTX), 51 received mepolizumab (MEPO), and 33 received omalizumab (OMA). At the time of inclusion, the median Birmingham Vasculitis Activity Score (BVAS) was 8.5 (interquartile range [IQR] 5-13) in the RTX group, while the median BVAS in the OMA group was 2 (IQR 1-4.5) and the median BVAS in the MEPO group was…

AdultMalemedicine.medical_specialtyImmunologyBirmingham Vasculitis Activity ScoreOmalizumabOmalizumabChurg-Strauss SyndromeAntibodies Monoclonal Humanized03 medical and health sciences0302 clinical medicineRheumatologyInterquartile rangeRecurrenceInternal medicinemedicineImmunology and AllergyHumansImmunologic Factors030212 general & internal medicineTreatment FailureAdverse effectGlucocorticoidsAgedRetrospective Studies030203 arthritis & rheumatologyBiological Productsbusiness.industryMiddle Agedmedicine.diseaseAsthmaTreatment OutcomeRituximabFemaleVasculitisbusinessGranulomatosis with polyangiitisRituximabMepolizumabmedicine.drugArthritisrheumatology (Hoboken, N.J.)References
researchProduct

Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis:A Randomized, Placebo-Controlled, Phase II Study

2017

Objective To determine the effect of selexipag, an oral, selective IP prostacyclin receptor agonist, on the frequency of attacks of Raynaud's phenomenon (RP) in patients with systemic sclerosis (SSc). Methods Patients with SSc-related RP were randomized 1:1 to placebo (n = 38) or selexipag (n = 36) in individualized doses (maximum of 1,600 μg twice daily) during a 3-week titration period. The primary end point was the weekly average number of RP attacks during the study maintenance period, analyzed using a Bayesian approach with a negative binomial model adjusted for baseline number of RP attacks. Other outcome measures included Raynaud's Condition Score (RCS), RP attack duration, and treat…

AdultMalemedicine.medical_specialtyImmunologyPhases of clinical researchSelexipagPlaceboSeverity of Illness Indexlaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodRheumatologyRandomized controlled triallawInternal medicineAcetamidesSeverity of illnessClinical endpointHumansImmunology and AllergyMedicine030212 general & internal medicineAdverse effectAntihypertensive Agents030203 arthritis & rheumatologyScleroderma Systemicbusiness.industryBayes TheoremRaynaud DiseaseMiddle AgedClinical trialTreatment OutcomechemistryPyrazinesFemalebusiness
researchProduct

The in vitro addition of methotrexate and/or methylprednisolone determines peripheral reduction in Th17 and expansion of conventional Treg and of IL-…

2014

The aim of our study was to evaluate methotrexate (MTX) and methylprednisolone (MP) effect on peripheral Th17 and Treg subsets in patients with rheumatoid arthritis (RA). We enrolled 15 patients (10 early RA and 5 long-standing disease) with active RA and 10 age-matched healthy donors as controls. Frequencies of Th17 and Treg were quantified using flow cytometry before and after in vitro addition of MTX, MP or both drugs. Our results showed a reduction in the overall Th17 population followed by an increase in Th17 IL-10+ and Treg, after in vitro treatment of PBMCs with the drugs in patients with early RA. Long-standing disease patients showed a less evident increase in Treg cells and less e…

AdultMalemedicine.medical_specialtyImmunologyPopulationArthritischemical and pharmacologic phenomenaPeripheral blood mononuclear cellMethylprednisoloneT-Lymphocytes RegulatoryArthritis RheumatoidRheumatologyInternal medicinemedicineImmunology and AllergyHumanseducationRheumatoid arthritieducation.field_of_studybusiness.industryhemic and immune systemsMiddle Agedmedicine.diseaseRheumatologyInterleukin-10TregSettore MED/16 - ReumatologiaMethotrexateMethylprednisoloneRheumatoid arthritis Th17 TregRheumatoid arthritisAntirheumatic AgentsImmunologyTh17 CellsMethotrexateFemaleTh17Interleukin 17businessmedicine.drug
researchProduct

Improved effectiveness from individualized dosing of self-administered biologics for the treatment of moderate-to-severe psoriasis: a 5-year retrospe…

2019

Background: Biologics for moderate-to-severe psoriasis are expensive and treatment substitutions may vastly increase cost. Moreover, administration regimens in routine practice may differ from recommended guidelines. Objectives: To evaluate long-term effectiveness, regimen, drug-survival, and efficiency of self-administered biologics in clinical practice. Methods: We performed a 5-year retrospective study in 72 patients (44 ± 14 years old) with moderate-to-severe psoriasis at the University Hospital La Plana (Vila-real, Spain), treated with subcutaneous biologics. We determined the effectiveness (PASI 75 or PASI < 5), and drug-survival using Kaplan-Meier estimates, and analyzed reasons for …

AdultMalemedicine.medical_specialtyIndividualized dosingCost effectivenessefficacySelf AdministrationKaplan-Meier EstimateDermatologyRoutine practiceDrug CostsustekinumabEtanercept030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineChart reviewPsoriasisUstekinumabmedicineHumansPsoriasisbiologicsIntensive care medicinecost-effectivenessRetrospective Studies030203 arthritis & rheumatologyBiological ProductsDrug Substitutionbusiness.industryModerate to severe psoriasisAdalimumabpsoriasisanti-TNFpersistenceMiddle Agedmedicine.diseaseUniversity hospitalSpainFemaleUstekinumabbusinessmedicine.drugJournal of Dermatological Treatment
researchProduct

Autoantibodies to the islet antigen ICA69 occur in IDDM and in rheumatoid arthritis.

1995

Islet cell antigen (ICA) 69 is a newly-recognized islet cell antigen to which autoantibodies have been observed in prediabetic relatives of patients with insulin-dependent-diabetes mellitus (IDDM). Here we extend the earlier analysis of ICA69 antibodies to patients with recent-onset IDDM and to patients with other immune-mediated diseases. ICA69 antibodies were determined by Western blot using an affinity purified recombinant fusion protein of ICA69 and maltose binding protein. ICA69 antibody quantities were determined as titres using a titration curve of a standard serum as reference. Mean logarithmic ICA69 antibody titres were 3.4 (+/- 1.4) in 99 patients with acute IDDM compared to 2.8 (…

AdultMalemedicine.medical_specialtyMultiple SclerosisTime Factorsendocrine system diseasesAdolescentEndocrinology Diabetes and MetabolismRecombinant Fusion ProteinsBlotting WesternArthritisAutoantigensArthritis RheumatoidAntigenCrohn DiseaseInternal medicineImmunopathologyInternal MedicinemedicineHumansFamilyChildAutoantibodiesAutoimmune diseasegeographygeography.geographical_feature_categorybiologybusiness.industryAutoantibodyThyroiditis AutoimmuneInfantMiddle AgedIsletmedicine.diseaseGraves DiseaseEndocrinologyDiabetes Mellitus Type 1Rheumatoid arthritisChild PreschoolImmunologybiology.proteinColitis UlcerativeFemaleAntibodybusinessFollow-Up StudiesDiabetologia
researchProduct